Compare Novartis AG (NVS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs DENTSPLY SIRONA Inc — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.70B). The key difference: Novartis AG is far larger — about 161.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| NVS | XRAY | |
|---|---|---|
Market Cap | $274.00B | $1.70B |
Volume | 1,852,137 | 4,220,050 |
Sector | Health | Health |
52-Week High | $168.62 | $14.68 |
52-Week Low | $121.80 | $8.52 |
Typical Hold Time | 82 Days | 72 Days |
Enterprise Value | $315.32B | $3.78B |
Dividend Yield | 3.31% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with bearish technical signals and declining revenue trends. The company reported Q2 2026 earnings beat but faces margin pressure and negative profitability metrics. Recent news highlights institutional stake increases and ongoing restructuring efforts amid challenging dental market conditions.
The stock presents a high-risk opportunity with analyst consensus target of $13.40 suggesting 54% upside potential. However, persistent net losses, declining revenue, and bearish technical indicators warrant caution. Recovery depends on successful execution of turnaround initiatives and market share stabilization in competitive dental equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
